Literature DB >> 6895907

Studies on the mechanism of NK cell lysis.

P C Quan, T Ishizaka, B R Bloom.   

Abstract

The mechanism of cytolysis by murine NK cells was analyzed using a variety of metabolic inhibitors that have proven informative in studying the lytic mechanism of CTL and the mechanism of histamine release by mast cells. Target cell binding occurred in the absence of calcium and was inhibited by only one of the agents studied, cytochalasin B. Lysis was initiated by addition of Ca2+ ions, as in the case of CTL. Subsequent to target cell binding, but prior to programming for lysis by Ca2+, NK cell lytic activity could be suppressed by inhibitors of chymotrypsin-like, but not trypsin-like proteases, in contrast to CTL. In addition, 3-deaza-SIBA, an inhibitor of transmethylation reactions and quinacrine, an inhibitor of phospholipase A2, appear to act before the Ca2+-dependent programming for lysis. Sr2+ ions blocked the lytic function, as did trifluoperazine (stelazine), the former presumably competing for ionic calcium, the latter known to block binding of Ca2+ to calmodulin. 8Br-cAMP and colchicine blocked later steps required for lysis. With the possible exception of trifluoperazine, all of the agents that blocked NK cell lysis are known to inhibit histamine release from mast cells. These results lend support to the stimulus-secretion model, originally proposed to explain the mechanism of CTL cytolysis, as relevant to the mechanism of lysis by NK cells.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6895907

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  21 in total

1.  Natural killer and lectin-dependent cytotoxic activities of Kurloff cells: target cell selectivity, conjugate formation, and Ca++ dependency.

Authors:  N Pouliot; K Maghni; F Blanchette; L Cironi; P Sirois; J Stankova; M Rola-Pleszczynski
Journal:  Inflammation       Date:  1996-12       Impact factor: 4.092

2.  Effects of inhibitors of tumoricidal activity upon schistosomulum killing by activated macrophages.

Authors:  S L James; J A Glaven
Journal:  Infect Immun       Date:  1987-12       Impact factor: 3.441

3.  Inhibition of natural killer-cell mediated cytolysis with monoclonal antibodies to restricted and non-restricted epitopes of the leucocyte common antigen.

Authors:  G C Starling; S E Davidson; J L McKenzie; D N Hart
Journal:  Immunology       Date:  1987-07       Impact factor: 7.397

4.  Murine lymphocytes with natural killer activity express CTL-derived serine protease genes.

Authors:  S K Anderson; K K Hong; D W Hoskin; W Abramow-Newerly; G M Fulop; R A Phillips; N Hozumi; J C Roder
Journal:  Immunology       Date:  1989-06       Impact factor: 7.397

5.  Cloning and chromosomal assignment of a human cDNA encoding a T cell- and natural killer cell-specific trypsin-like serine protease.

Authors:  H K Gershenfeld; R J Hershberger; T B Shows; I L Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  1988-02       Impact factor: 11.205

Review 6.  Natural killer cells in resistance to virus-infected cells.

Authors:  B Rager-Zisman; B R Bloom
Journal:  Springer Semin Immunopathol       Date:  1982

7.  Regulation of human natural killing by lysosomotropic and thiol-reactive agents.

Authors:  H Shau; J R Dawson
Journal:  Immunology       Date:  1985-08       Impact factor: 7.397

8.  Aggregation of human polymorphonuclear leucocytes during phagocytosis of bacteria.

Authors:  P A Henricks; M E van der Tol; J Verhoef
Journal:  Immunology       Date:  1984-08       Impact factor: 7.397

9.  Antibody- and interferon-dependent killer cells are part of the NK cell receptor positive subpopulation of human peripheral blood cells.

Authors:  M Ullberg; M Jondal
Journal:  Clin Exp Immunol       Date:  1983-07       Impact factor: 4.330

10.  Potassium channels mediate killing by human natural killer cells.

Authors:  L Schlichter; N Sidell; S Hagiwara
Journal:  Proc Natl Acad Sci U S A       Date:  1986-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.